Healius Limited (ASX: HLS)
Australia flag Australia · Delayed Price · Currency is AUD
1.365
-0.035 (-2.50%)
Dec 20, 2024, 4:10 PM AEST

Healius Company Description

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia.

The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.

The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands.

It operates medical laboratories, medical centers, patient collection centers, and community imaging centers.

The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018.

Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

Healius Limited
Country Australia
Founded 1994
Industry Diagnostics & Research
Sector Healthcare
Employees 9,658
CEO Paul Anderson

Contact Details

Address:
161 Castlereagh Street
Sydney, Victoria 2000
Australia
Phone 61 2 9432 9400
Website healius.com.au

Stock Details

Ticker Symbol HLS
Exchange Australian Securities Exchange
Fiscal Year July - June
Reporting Currency AUD
ISIN Number AU0000033359
SIC Code 8011

Key Executives

Name Position
Paul D. Anderson B.Com., C.A. MD, Chief Executive Officer and Director
Stephen Humphries B.Sc. Chief Financial Officer& Company Secretary
Dr. Jan Van Rooyen Head and Group Executive of Healius Pathology
Paula Bayliss Group Executive of People and Culture
John McKechnie Advisor
Dr. Phil Lucas Chief Executive of Lumus Imaging
Ian Mcphan Chief Operating Officer of Healius Pathology
Sharon Ng Head of Group FP&A
Arjun Narang Group Executive of Operations Transformation
Jon Eide Group Executive of Commercial and Customer